Table 1 Results and groups of host quality of immune function.

From: Prognostic implications of N6-methyladenosine RNA regulators in breast cancer

Item

Patient 1

Patient 2

Patient 3

Patient 4

Patient 5

Patient 6

Patient 7

Patient 8

Patient 9

Patient 10

Patient 11

Reference range

ZLBXB-FZ1

19.55

20.4

16.44

27.48

20.5

39.57

18.22

45.72

32.33

39.03

20.05

27.90–37.3

CD3 + 

69.65

85.44

84.45

79.04

73.74

66.35

59.19

66.33

68.86

79.08

75.08

26.00–76.80

CD3 + CD4 + CD8-

35.67

54.32

53.39

43.43

31.6

44.78

42.21

43.01

41.94

48.96

47.14

30–46

CD3 + CD4-CD8 + 

28.48

28.21

28.23

33.55

32.53

21.73

15.72

25.39

26.54

27.14

25.51

19.2–33.6

CD4 + CD8 + 

0.97

1.64

0.85

1.5

0.5

0.45

0.15

2.87

0.46

0.17

0.23

0–2.00

CD4-CD8-

6.05

4.54

2.78

3.46

11.53

3.69

1.75

1.24

1.6

4.32

2.93

0–12.00

CD3-CD19 + 

13.72

3.01

4.34

2.61

4.63

16.71

24.09

16.96

23.42

12.31

14.96

8.50–14.50

CD3-CD16/56 + 

16.51

11.55

11.07

18.25

21.57

11.46

15.42

16.71

7.76

7.88

9.96

9.50–23.50

CD3 + CD16/56 + 

4.59

7.56

5.04

3.61

7.9

0.49

1.45

4.79

6.96

3.39

1.04

–

Comprehensive score

84

35

52

32

67

375

367

353

693

352

397

–

High or low flag

L

L

L

L

L

H

H

H

H

H

H

–

Back to article page